BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned about the near-term growth trajectory given management expects Q3 revenue to be below Q2 based on patient pausing trends. Following the quarterly report, the firm updated its model to reflect decreased near-term Vyjuvek revenues and pushed back launches for KB407 and KB408.
-
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRYS:
Disclaimer & DisclosureReport an Issue
 to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned about the near-term growth trajectory given management expects Q3 revenue to be below Q2 based on patient pausing trends. Following the quarterly report, the firm updated its model to reflect decreased near-term Vyjuvek revenues and pushed back launches for KB4){kind=link}